Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Evaluating renal and pulmonary disease in pediatric-onset autoantibody-associated vasculitis: disease course, outcomes, and predictors of outcome.

EF 2023-24

Résumé
Our research group is focused on improving the lives of young people who have a rare disease (~ 1 child per 250,000) known as “vasculitis.” This disease causes damage to the blood vessels in the body’s major organs – most often the kidneys and the lungs. Although many of the newer medications have significantly improved the lives of children with vasculitis (without which most children would die within one year of diagnosis), they can cause serious side effects. As a result, only kids with stubborn disease that doesn’t improve or kids with aggressive disease that can rapidly cause organ failure, should be given such treatments at high doses and/or over a long time. However, it is difficult to predict at the time of diagnosis, which children will have mild disease, and which will have worse disease. The BC Children’s Hospital’s doctors and scientists have been gathering data on more than 400 children with a certain type of vasculitis from all around the world for more than ten years. My project will use this valuable data to answer questions such as: How does vasculitis progress in children over time (this is called ‘disease course’)? What level of lung and/or kidney function can be expected at six months, one year and two years after diagnosis (‘disease outcome’)? Are there signs at diagnosis that can tell us if a child will have a better or worse outcome (‘disease predictors’)? This study of childhood vasculitis will be the largest of its kind. The results of the study, especially the discovery of predictors of outcome, will help doctors counsel children and their families. It will also help us understand if lung and kidney disease get worse or better over time, why this could happen, and help guide treatment decisions to give each child the best care possible.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
506209
Name
Toor Kirandeep K
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Evaluating renal and pulmonary disease in pediatric-onset autoantibody-associated vasculitis: disease course, outcomes, and predictors of outcome.
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Autoantibodies; Disease Course; Disease Outcome; Kidneys; Lungs; Pediatric Vasculitis; Predictors
Abstract
Our research group is focused on improving the lives of young people who have a rare disease (~ 1 child per 250,000) known as “vasculitis.” This disease causes damage to the blood vessels in the body’s major organs – most often the kidneys and the lungs. Although many of the newer medications have significantly improved the lives of children with vasculitis (without which most children would die within one year of diagnosis), they can cause serious side effects. As a result, only kids with stubborn disease that doesn’t improve or kids with aggressive disease that can rapidly cause organ failure, should be given such treatments at high doses and/or over a long time. However, it is difficult to predict at the time of diagnosis, which children will have mild disease, and which will have worse disease. The BC Children’s Hospital’s doctors and scientists have been gathering data on more than 400 children with a certain type of vasculitis from all around the world for more than ten years. My project will use this valuable data to answer questions such as: How does vasculitis progress in children over time (this is called ‘disease course’)? What level of lung and/or kidney function can be expected at six months, one year and two years after diagnosis (‘disease outcome’)? Are there signs at diagnosis that can tell us if a child will have a better or worse outcome (‘disease predictors’)? This study of childhood vasculitis will be the largest of its kind. The results of the study, especially the discovery of predictors of outcome, will help doctors counsel children and their families. It will also help us understand if lung and kidney disease get worse or better over time, why this could happen, and help guide treatment decisions to give each child the best care possible.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Toor, Kirandeep K
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~